Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Glass Ceiling Report
- Law360 400
- NEWDiversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
Case Number:
Case Type:
IPR
Status:
Final Written Decision
Petitioner:
Nalox-1 Pharmaceuticals, LLC
Patent Owner:
Opiant Pharmaceuticals, Inc.
Patent Number:
Tech Center:
1600
-
Filed: February 19, 2019 00:00
Coverage
-
August 24, 2020
PTAB Upholds Entirety Of 3 Narcan Patents
The Patent Trial and Appeal Board has refused to invalidate three different patents covering Adapt Pharma Ltd.'s opioid overdose treatment Narcan, two of which had a different fate in district court.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
August 24, 2020